Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$31000.0.

  • Orchestra BioMed Holdings' Change in Receivables fell 18857.14% to -$31000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$78000.0, marking a year-over-year decrease of 36896.55%. This contributed to the annual value of -$22000.0 for FY2024, which is 83333.33% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Change in Receivables stood at -$31000.0 for Q3 2025, which was down 18857.14% from -$6000.0 recorded in Q2 2025.
  • Orchestra BioMed Holdings' Change in Receivables' 5-year high stood at $95000.0 during Q2 2023, with a 5-year trough of -$85000.0 in Q3 2023.
  • Over the past 4 years, Orchestra BioMed Holdings' median Change in Receivables value was -$4500.0 (recorded in 2025), while the average stood at -$6000.0.
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Change in Receivables was 940000.0% (2023), while the steepest drop was 63125.0% (2023).
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Change in Receivables stood at $16000.0 in 2022, then decreased by 18.75% to $13000.0 in 2023, then crashed by 392.31% to -$38000.0 in 2024, then increased by 18.42% to -$31000.0 in 2025.
  • Its last three reported values are -$31000.0 in Q3 2025, -$6000.0 for Q2 2025, and -$3000.0 during Q1 2025.